Overview of Q1 2025 Financial Results
BrainsWay Ltd. (NASDAQ: BWAY) recently shared its financial results for the one-quarter of 2025, revealing excellent growth and solid operational performance. The company achieved record-breaking sales totaling $11.5 million, which marks a significant 27% increase compared to the previous year's results.
Financial Highlights for the Quarter
The company reported impressive figures for operating profit and adjusted EBITDA. Specifically, operating profit reached $0.6 million, drastically up by 519% from just $0.1 million in Q1 2024. Adjusted EBITDA grew by 81%, rising to $1.3 million, compared to $0.7 million in the same quarter last year. This growth is essential, highlighting BrainsWay's efficient operational management and financial health.
Revenue Growth
Revenue saw a remarkable surge of 27%, emphasizing the growing demand for BrainsWay's Deep TMS systems. In total, 81 deep transcranial magnetic stimulation (Deep TMS™) systems were shipped during the quarter—a notable 42% increase over the 57 systems delivered in Q1 2024.
Gross Margin Stability
The gross margin for this quarter remained stable at 75%, consistent with the prior year. This shows that BrainsWay has successfully maintained profitability even while increasing its sales.
Operational Developments and Future Outlook
BrainsWay continues to innovate and evolve within the mental health treatment sector. As of March 31, 2025, the company held a robust cash position of $71.9 million. This financial stability enables the company to pursue strategic initiatives aimed at enhancing its product offerings and market reach.
Clinical Trials and Collaborations
The company is making strides with its randomized, multicenter U.S. clinical trial targeting an accelerated treatment protocol for major depressive disorder. Furthermore, BrainsWay has been working closely with the Israel Ministry of Defense to qualify patients suffering from post-traumatic stress disorder (PTSD) for Deep TMS treatments. These collaborations highlight BrainsWay's commitment to advancing mental health treatments and expanding its market presence.
Full-Year Financial Guidance
BrainsWay has reaffirmed its guidance for the full year of 2025, expecting revenues between $49 million to $51 million, with an operating profit of 3% to 4%. Additionally, the company anticipates an adjusted EBITDA of 11% to 12% for the fiscal year. These projections signify confidence in sustained growth and market demand for its products.
Comments from Management
CEO Hadar Levy remarked, "We continued to rapidly increase our share in the TMS market during Q1 2025. The growing demand and utilization of our technology for various indications, like OCD and anxious depression, is a testament to our robust sales strategy and enterprise relationships. Our focus remains on developing key partnerships that foster meaningful recurring revenue and help us build a solid sales backlog."
Path Forward
Looking ahead, BrainsWay aims to leverage upcoming product advancements, including the next-generation Deep TMS 360™ system. It plans to expand into new therapeutic indications and broaden its accessibility through clinical data support. As BrainsWay enhances its market presence across Canada, Asia, India, and Europe, these developments pave the way for significant growth potential.
Frequently Asked Questions
What were BrainsWay's sales figures for Q1 2025?
BrainsWay reported record sales of $11.5 million in Q1 2025, a 27% increase from Q1 2024.
How much did BrainsWay's Adjusted EBITDA grow?
Adjusted EBITDA rose to $1.3 million, reflecting an 81% increase compared to Q1 2024.
What is the company's guidance for the full year of 2025?
BrainsWay expects revenues of $49 million to $51 million with an operating profit of 3% to 4% and Adjusted EBITDA of 11% to 12%.
What new initiatives are being pursued?
The company is engaged in clinical trials aimed at new treatment protocols for major depressive disorder and collaborations related to PTSD therapies.
What is BrainsWay's current cash status?
As of March 31, 2025, BrainsWay holds $71.9 million in cash and short-term deposits.
